What's the highest dose of Mounjaro, and when do you reach it?

What are all the Mounjaro doses, and how does the schedule progress?

Mounjaro is licensed in the UK at six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. Each pen contains four weekly doses, so one pen covers a calendar month. The titration schedule moves upward in roughly four-week intervals, though your prescriber sets the actual pace based on how you're getting on. A question our prescribers hear most weeks is whether staying longer at a lower dose means it's not working, in most cases, it simply means the body is still adjusting, and a slower climb often means fewer side effects overall.

The 2.5mg starting dose has a specific purpose: it's there to settle your digestive system into the mechanism of the medicine, not to produce measurable weight loss. Side effects (typically nausea, loose stools or constipation) are most common at the start and after each step up. Staying at each dose for the full four weeks before moving on gives the body time to adapt. You can find more detail on how the lower doses fit into the overall programme on our Mounjaro 5mg page.

What nobody should tell you is the exact schedule you personally ought to follow. The NHS tirzepatide guidance is clear that dosing decisions belong to the prescribing clinician, and your Patient Information Leaflet is the authoritative reference for the specifics. Titration is not a ladder you climb as fast as possible, it's a clinical process.

Does everyone reach the 15mg maximum dose?

No, and that's fine. If you want to understand what the highest dosage of Mounjaro involves and who typically reaches it, the licensed maximum is 15mg, but the clinical goal is the highest dose you tolerate comfortably, which may be lower. Some people find 10mg or 12.5mg gives them good appetite suppression with manageable side effects and see no benefit in pushing further. Others tolerate the full titration without difficulty and reach 15mg within six months of starting.

What the trial data tell us is that greater average weight loss was observed at higher doses in the SURMOUNT programme, which involved thousands of adults across its trials. But individual response varies, and clinical trials measure group averages. Your prescriber's job is to match the dose to you (your response, your tolerance and your health picture) rather than to hit a number on a chart.

It is also worth knowing that if you haven't lost at least 5% of your body weight after six months on the highest dose you can tolerate, NICE guidance (TA1026) recommends reviewing whether continuing is appropriate. That review is part of what a proper clinical oversight structure is supposed to catch. If you're curious about how that guidance shapes private treatment decisions, our page on reaching the maximum dose covers what typically happens next.

What does the evidence say about weight loss at the highest Mounjaro dose?

SURMOUNT-1 (the pivotal phase 3 trial) found that adults without diabetes who reached 15mg lost an average of around 20–21% of body weight over 72 weeks, compared with around 3% in the placebo group. That is a substantial difference, and it underpins why NICE recommended tirzepatide for weight management in December 2024.

The head-to-head data are also relevant here. SURMOUNT-5 (published in the New England Journal of Medicine, 2025) compared tirzepatide directly with semaglutide 2.4mg and found greater average weight reduction with tirzepatide, a finding the NICE committee acknowledged in its appraisal. Context matters though: Wegovy's newer 7.2mg maintenance dose, approved by the MHRA in early 2026, narrows that gap at the highest semaglutide level.

For a broader picture of how both medicines compare at their respective ceilings, our weight-loss treatment overview sets out the options side by side. And for anyone thinking about what private access to Mounjaro actually involves, our guide to getting Mounjaro through a regulated online pharmacy explains the clinical process in plain terms. The evidence at 15mg is compelling, but compelling evidence is a reason to have a proper clinical conversation, not to self-escalate.

What happens if you can't tolerate the higher doses?

Tolerability is the practical limit on how far most people travel up the dose ladder. Gastrointestinal effects (nausea, vomiting, diarrhoea, reflux) are most intense at the beginning of a new dose level and typically settle within one to two weeks. For some people they don't fully settle, and forcing the next increase would mean trading off meaningful discomfort against marginal additional weight loss.

If your prescriber decides a lower maintenance dose is right for you, that's a clinical decision, not a failure. A smaller average loss that you can sustain long-term is almost always preferable to a theoretical maximum that makes you miserable. Prescribers may also slow the titration pace rather than cap the ceiling (spending six or eight weeks at one dose before moving on) which often resolves tolerance issues without abandoning the goal of reaching a higher strength. If you are weighing up your options, our guide to finding the best dose of Mounjaro for weight loss can help you think through what to discuss with your prescriber.

For questions specific to your own situation, our frequently asked questions cover many of the common concerns, and our clinical team is available seven days a week for aftercare. If you'd like a prescriber to assess your eligibility and discuss what dose progression might look like for you, you can start your free consultation today.